Dräger India collaborates with Breach Candy Hospital to advance clinical education

Dräger India and Breach Candy Hospital have partnered to enhance clinical education and skill development for healthcare professionals. This collaboration brings the Dräger Medical Academy to Mumbai, offering digital learning modules and VR-based simulation training to bridge skill gaps and improve patient safety. The initiative aims to foster continuous learning and readiness in India's evolving healthcare landscape.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/n4tzOLc
via IFTTT

Read More

Navigating environmental shifts: How proactive hygiene shapes a child's future

In today's unpredictable climate, raising children requires a proactive approach to health beyond traditional methods. Savlon Swasth India Mission's podcast, The Doc's Pod, emphasizes science-backed hygiene practices as a strategic tool for physical empowerment. By integrating habits like regular handwashing and surface sanitization, families can build a robust foundation for enduring health and cognitive development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nha8Qw1
via IFTTT

Read More

Alembic Pharma gets USFDA nod for generic drug

Alembic Pharmaceuticals has secured approval from the US health regulator for a generic seizure medication. The company received final clearance from the USFDA for Lamotrigine orally disintegrating tablets. This drug is therapeutically equivalent to GlaxoSmithKline's Lamictal. It is used for various seizure types in patients aged two and older. The market for this medication is estimated at USD 27 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1U7YSVz
via IFTTT

Read More

Zydus plans launch of semaglutide generic in reusable pen form

Zydus Lifesciences is set to launch a generic version of the weight-loss injection semaglutide next month. The drug will be available under brand names Semaglyn, Mashema, and Altreme. Zydus will offer a unique reusable pen for easier dosage adjustment. This move aims to simplify treatment for patients managing Type 2 diabetes and obesity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fEWJ2gU
via IFTTT

Read More

GST department initiates inspection and search ops at Lupin's office

Maharashtra's Goods & Services Tax Department has initiated inspection and search proceedings at Lupin's registered office. The pharmaceutical giant stated that these actions will not impact its financials, operations, or other activities. Lupin recently reported strong Q3 FY26 growth, with highest-ever US sales and double-digit growth in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/raeUq9M
via IFTTT

Read More

India’s weight-loss drugs to get cheaper as semaglutide patent expires

Affordable generic versions of popular weight-loss drugs Wegovy and Ozempic are set to launch in India. This follows the patent expiry of semaglutide, the key ingredient. Several Indian pharmaceutical companies are preparing for a March 21 launch.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GcepZab
via IFTTT

Read More

Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say

Dr Reddy's Laboratories is poised to launch its generic semaglutide injection, potentially named Obeda, in India by March. This move anticipates the March 2026 patent expiry for the active ingredient in Novo Nordisk's Ozempic and Wegovy. The Indian drugmaker plans competitive pricing, aiming to capture a significant share of the growing diabetes and obesity market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rkOETu6
via IFTTT

Read More